Cytosorbents Corporation (CTSO)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytosorbents Corporation (“Cytosorbents” or “the Company”) (NASDAQ: CTSO). Investors who purchased Cytosorbents securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Cytosorbents has violated federal securities laws.
Investigation Details:
On December 28, 2023, Cytosorbents issued a press release announcing that its pivotal trial investigating the ability of its device candidate, DrugSorb®-ATR, to reduce perioperative bleeding in patients on ticagrelor (Brilinta®, Brilique® – AstraZeneca) undergoing cardiothoracic surgery before completing the recommended washout period, “did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries.” On this news, Cytosorbents’ stock price fell $0.545 per share, or 33.44%, to close at $1.085 per share on December 28, 2023.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Cytosorbents securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson